References
1) Mandler et al. (2004), Herceptin-geldanamycin immunoconjugates: pharmacokinetics, biodistribution, and enhanced antitumor activity; Cancer Res., 64 1460
2) Mandler et al. (2002), Modifications in synthesis strategy improve the yield and efficacy of geldanamycin-herceptin immunoconjugates; Bioconj. Chem., 13 786
3) Mandler et al. (2000), Immunoconjugates of geldanamycin and anti-HER2 monoclonal antibodies: antiproliferative activity on human breast carcinoma cell lines; J. Natl. Cancer Inst., 92 1573
